Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

ema.europa.eu

What's new

Get the latest updates from What's new directly as they happen.

Follow now 334 followers

Latest posts

Last updated about 13 hours ago

Human medicines European public assessment report (EPAR): Lacosamide Adroiq, lacosamide, Date of authorisation: 31/05/2023, Revision: 8, Status: Authorised

about 13 hours ago

Human medicines European public assessment report (EPAR): Lacosamide Adroiq, lacosamide, Date of...

Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation: 26/05/2023, Revision: 6, Status: Authorised

about 13 hours ago

Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation...

PSUSA/00010462/202510

about 13 hours ago

PSUSA/00010462/202510

PSUSA/00000419/202509

about 13 hours ago

PSUSA/00000419/202509

Presentation - Why are NAMs important? (S. Ponzano)

about 14 hours ago

Presentation - Why are NAMs important? (S. Ponzano)

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 9, Status: Authorised

about 14 hours ago

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation...

Applications for new human medicines under evaluation: August 2026

about 14 hours ago

Applications for new human medicines under evaluation: August 2026

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 17, Status: Authorised

about 14 hours ago

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation...

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 23, Status: Authorised

about 15 hours ago

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted)...